Attached files

file filename
10-Q/A - 10-Q/A - MABVAX THERAPEUTICS HOLDINGS, INC.mbvx10qa_june302015.htm
EX-99.1 - MABVAX THERAPEUTICS, INC. GRANTED AND PENDING PATENTS AND APPLICATIONS - MABVAX THERAPEUTICS HOLDINGS, INC.ex99-1.htm
EX-32 - CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex32.htm
EX-10.9 - EXCLUSIVE LICENSE TO UNIMOLECULAR ANTIBODIES, DATED OCTOBER 13, 2011, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-9.htm
EX-10.5 - EMPLOYMENT AGREEMENT, DATED JULY 21, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND PAUL MAFFUID, PH.D. - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-5.htm
EX-31.2 - CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-2.htm
EX-10.4 - SECOND AMENDMENT TO THAT STANDARD INDUSTRIAL NET LEASE, DATED AUGUST 1, 2012, BY AND BETWEEN THE COMPANY AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-4.htm
EX-10.3 - FIRST AMENDMENT TO THAT STANDARD INDUSTRIAL NET LEASE, DATED MAY 6, 2010, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-3.htm
EX-10.8 - RESEARCH AND LICENSE AGREEMENT, DATED AS OF APRIL 7, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-8.htm
EX-10.6 - DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT, DATED APRIL 15, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND GALLUS BIOPHARMACEUTICALS NJ, LLC - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-6.htm
EX-10.7 - EXCLUSIVE LICENSE AGREEMENT FOR "POLYVALENT CONJUGATE VACCINES FOR CANCER" (SK#14491), DATED AS OF JUNE 30, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-7.htm
EX-10.2 - STANDARD INDUSTRIAL NET LEASE, DATED AS OF MAY 23, 2008, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND SORRENTO SQUARE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-2.htm
EX-10.10 - OPTION AGREEMENT, DATED AUGUST 29, 2014, BY AND BETWEEN MABVAX THERAPEUTICS, INC. AND JUNO THERAPEUTICS, INC. - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-10.htm
EX-10.11 - SBIR CONTRACT FROM NATIONAL CANCER INSTITUTE - MABVAX THERAPEUTICS HOLDINGS, INC.ex10-11.htm
EX-31.1 - CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER REQUIRED BY SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 - MABVAX THERAPEUTICS HOLDINGS, INC.ex31-1.htm
Exhibit 10.1
 
Effective: September 8, 2014
 
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
 
The Board of Directors of MabVax Therapeutics Holdings, Inc. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”) which establishes compensation to be paid to non-employee directors of the Company, effective as of September 8, 2014 (the “Effective Time”), to provide an inducement to obtain and retain the services of qualified persons to serve as members of the Company’s Board of Directors.
 
Applicable Persons
 
This Policy shall apply to each director of the Company who is not an employee of, or compensated consultant to, the Company or any Affiliate (each, an “Outside Director”). “Affiliate” shall mean a corporation which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to Section 424 of the Internal Revenue Code of 1986, as amended.
 
Stock Option Grants
 
All stock option amounts set forth herein shall be subject to automatic adjustment in the event of any stock split or other recapitalization affecting the Company’s common stock.
 
Annual Stock Option Grants
 
Each Outside Director shall be granted a non-qualified stock option to purchase 6,948 shares of the Company’s common stock under the Company’s 2014 Employee, Director and Consultant Equity Incentive Plan (the “Stock Plan”) each year on the yearly anniversary of such Outside Director’s first date of service as an Outside Director.
 
Unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant, all Annual Stock Options granted under this Policy shall (i) vest one year from the date of the grant, subject to the Outside Director’s continued service on the Board of Directors; (ii) have an exercise price equal to the fair market value of the Company’s common stock as determined in the Stock Plan on the date of grant; and (iii) contain such other terms and conditions as the Board of Directors or the Compensation Committee shall determine.
 
Initial Stock Option Grant For Newly Appointed or Elected Directors
 
Each new Outside Director shall be granted a non-qualified stock option to purchase 11,116 shares of the Company’s common stock under the Stock Plan on the date of his or her initial appointment or election to the Board of Directors. Unless otherwise specified by the Board of Directors or the Compensation Committee at the time of grant, all Initial Stock Options granted under this Policy shall (i) be fully vested on the date of the grant; (ii) have an exercise price equal to the greater of (x) $4.48 per share or (y) the fair market value of the Company’s common stock as determined in the Stock Plan on the date of grant; and (iii) contain such other terms and conditions as the Board of Directors or the Compensation Committee shall determine.
 
Cash Fees
 
Cash Payments
 
The following annual cash fees shall be paid to the Outside Directors serving on the Board of Directors and the Audit Committee, Compensation Committee and Nominating and Governance Committee, as applicable.
 
Board of Directors or Committee of Board of Directors
  
Amount for Member
 
Board of Directors (Annual)
  
$
12,000
  
Attendance at Board Meeting in person (per meeting)
  
$
1,250
  
Attendance at Board Meeting telephonically (per meeting)
  
$
750
  
 
 
 

 
 
Payment Terms for All Cash Fees
 
Cash payments payable to Outside Directors shall be paid monthly in arrears as of the first day of the calendar month. For any portion of a fiscal year in which the Effective Time occurs, annual payments shall be pro-rated beginning on the first day of the calendar month in which the Effective Time occurs.
 
Following an Outside Director’s first election or appointment to the Board of Directors, such Outside Director shall receive his or her cash compensation pro-rated beginning on the first day of the calendar month in which he or she was initially appointed or elected. If an Outside Director dies, resigns or is removed during any quarter, he or she shall be entitled to a cash payment on a pro rated basis through his or her last day of service.
 
Expenses
 
Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each Outside Director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board of Directors and Committees thereof or in connection with other business related to the Board of Directors.
 
Amendments
 
The Compensation Committee or the Board of Directors shall review this Policy from time to time to assess whether any amendments in the type and amount of compensation provided herein should be adjusted in order to fulfill the objectives of this Policy.